Alpha Cognition (ACOG) vs Cartesian Therapeutics (RNAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alpha Cognition (ACOG) has outperformed Cartesian Therapeutics (RNAC) over the past year, gaining 23.0% versus a loss of 31.4%. Cartesian Therapeutics is the larger company by market cap ($204.5 million vs $195.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACOG | RNAC |
|---|---|---|
| Share price | $8.97 | $6.76 |
| Market cap | $195.35M | $204.53M |
| 1-day change | -0.77% | +1.20% |
| YTD return | +39.08% | -7.35% |
| 1-year return | +22.99% | -31.42% |
| 5-year return | — | -94.79% |
| EPS (TTM) | $-1.32 | $-5.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.14 | $11.00 |
| 52-week low | $4.50 | $5.60 |
| Distance from 52-week high | -11.54% | -38.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +100.67% | +398.08% |
| Average volume | 124.69K | 131.99K |
| Shares outstanding | 21.78M | 30.26M |
| Employees | 71 | 75 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACOG has outperformed RNAC by 54.4 percentage points over the past year.
- The two companies sit in different sectors: Alpha Cognition in Healthcare and Cartesian Therapeutics in Health Care.
About Alpha Cognition
ACOG stock →Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Healthcare · Biotechnology · 71 employees
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
ACOG vs RNAC FAQ
Which is bigger, Alpha Cognition or Cartesian Therapeutics?
Cartesian Therapeutics (RNAC) is larger, with a market capitalization of $204.53M compared with $195.35M for Alpha Cognition (ACOG).
Which stock has performed better over the past year, ACOG or RNAC?
ACOG returned +22.99% over the past 12 months, compared with -31.42% for RNAC (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Cognition and Cartesian Therapeutics in the same industry?
No. Alpha Cognition is in the Healthcare sector, while Cartesian Therapeutics is in Health Care.